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ABSTRACT 
 
Current interventions to reduce skeletal fragility are insufficient at enhancing both the 
quantity and quality of bone when attempting to improve overall mechanical integrity. 
Bisphosphonates, such as Zoledronate (ZOL), are used to treat a variety of bone disorders by 
increasing bone mass to decrease fracture risk, but long-term use has been shown in some settings 
to compromise bone quality. Alternatively, Raloxifene (RAL) has recently been demonstrated to 
improve tissue quality and overall mechanical properties in a cell-independent manner by binding 
to collagen and increasing tissue hydration. We hypothesized that a combination of RAL and ZOL 
would improve mechanical and material properties of bone more than either monotherapy alone 
by enhancing both quantity and quality. In this study, wildtype (WT) and heterozygous (OIM+/-) 
male mice from the Osteogenesis Imperfecta (OI) murine model were treated with either RAL, 
ZOL, or both from 8 weeks to 16 weeks of age. Using the OIM model allows for investigation of 
therapeutic effects on a quality-based bone disease. Combination treatment resulted in higher 
trabecular architecture, cortical mechanical properties, and cortical fracture toughness in diseased 
mouse bone. Two fracture toughness properties, which are direct measures of the tissue’s ability 
to resist the initiation and propagation of a crack, were significantly improved with combination 
treatment in OIM+/- compared to control. There was no significant effect on fracture toughness 
with either monotherapy alone in either genotype. Following the mass-based effects of ZOL, 
trabecular bone volume fraction was significantly higher with combination treatment in both 
genotypes. Combination treatment resulted in higher ultimate stress in both genotypes. RAL and 
combination treatment in OIM+/- also increased resilience compared to the control. In conclusion, 
this study demonstrates the beneficial effects of using combination drug treatments to increase 
bone mass while simultaneously improving tissue quality, especially to enhance the mechanical 
integrity of diseased bone. Combination therapies could be a potential method to improve bone 
health and combat skeletal fragility on both the microscopic and macroscopic levels.  
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HIGHLIGHTS 
 Combination treatment of Raloxifene and Zoledronate was investigated in the 
Osteogenesis Imperfect murine model 
 Bone architecture, biomechanics, and fracture toughness were assessed in hindlimbs 
 Combination treatment followed the quantity-based effects of Zoledronate with 
increases in trabecular microarchitecture  
 Raloxifene drove the mechanical changes in the combination treatment 
 Fracture toughness improved only with combination treatment in heterozygous 
diseased bone 
 
1. INTRODUCTION 
 
Bisphosphonates (BPs) have been the gold standard to treat skeletal fragility and 
numerous bone disorders for the past 30 years. BPs increase bone mineral density which leads to 
decreased fracture risk in diseases such as postmenopausal osteoporosis, Paget’s disease, 
metastatic osteolytic lesions, and more recently, Osteogenesis Imperfecta (OI).[1-3]  BPs target 
osteoclasts and decrease their activity, which ultimately leads to the disruption of the bone 
remodeling process.[4] However, long term BP use may have unintended consequences.  The 
disruption of bone remodeling reduces the bone repair mechanism which can lead to the accrual 
of microdamage in the tissue, making the tissue more susceptible to failure.[5] BP use has also 
demonstrated an increase of non-enzymatic cross linking in the collagen matrix, which has been 
correlated with reduced post-yield mechanical properties.[6-8] Despite the positive mass-based 
effects BPs have in bone, tissue quality may not be optimal, making these treatments insufficient 
to overcome mechanical deficits that commonly manifest with disease. There is a need to 
simultaneously improve tissue quality while increasing mass.   
Raloxifene (RAL) is in a different class of FDA-approved drugs used to treat 
osteoporosis in post-menopausal women. The drug primarily acts in a cell-dependent manner as 
a Selective Estrogen Receptor Modulator (SERM) and combats bone loss by binding and 
signaling through estrogen receptors on osteoblasts.[9] Clinically, RAL reduces fractures by 
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~50% but with modest changes in remodeling and bone mineral density (BMD).[10-12] This 
observation suggests that the changes in mechanical integrity are driven by tissue quality 
changes versus altered mass or architecture. Recent work has demonstrated that RAL also 
exhibits cell-independent behavior by binding to collagen and increasing tissue hydration, 
leading to enhanced mechanical properties and fracture resistance.[13, 14] These cell-independent, 
material-based changes provide a unique opportunity to beneficially alter bone fracture 
resistance through changes in tissue quality, especially in disease states that are driven by 
inferior tissue properties.  
OI is a genetic disease in bone caused by a mutation in Type I collagen or related 
proteins. The mutated collagen leads to poor formation of the triple helical structure, driving 
quality-based deficiencies in the collagen-mineral composite.[15-17] These microscopic changes 
induce macroscopic effects and cause brittle bones and frequent fractures in patients suffering 
from the disease. The majority of fractures in OI patients occur at cortical regions of their long 
bones, and the femoral mid-diaphysis is particularly at risk due to load bearing during 
ambulation[18, 19]. Targeting quality at these regions is crucial to clinically reduce fractures in 
patients affected by OI.  
Previously, clinical research has shown potential benefits of using the combination of 
RAL and ZOL in osteoporotic women[20]. However, combination treatment has not been assessed 
in a disease where the mechanical deficits root from microscopic-level deficiencies in quality. In 
this study, the osteogenesis imperfecta murine (oim) model of OI allowed for investigation of 
how combination treatments impact the phenotype of a quality-based disease state[21], where 
adding more, poor quality, tissue with BPs might not be enough to overcome mechanical 
deficiencies. It was hypothesized that using the mass-based effects of BPs, in conjunction with 
the tissue level improvements noted with RAL, would improve bone mechanical properties and 
fracture resistance more than either monotherapy alone.  
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2. MATERIALS AND METHODS 
 
2.2 Animals and Treatment 
All protocols and procedures were performed with prior approval from the IU School of 
Medicine IACUC. Male wild-type (WT) and heterozygous (OIM +/-) mice were bred from 
heterozygous parental strains on a C57BL/6 background.[22] Beginning at 8 weeks of age, mice 
(n=13-15 per group) were injected subcutaneously with either RAL (0.5 mg/kg; 5x/week), 
zoledronate (ZOL; 80 µg/kg; at 8 weeks and 12 weeks of age), or the combination. Untreated 
controls were also included. These dosages were chosen based on previous research showing 
efficacy in vivo.[23-26] At 16 weeks of age, the mice were euthanized by CO2 asphyxiation, and the 
right femora and tibiae were harvested, stripped of soft tissue, and frozen wrapped in phosphate 
buffered saline (PBS)-soaked gauze at -20C. 
 
2.3 Microcomputed Tomography (µCT) and Architectural Analysis 
To determine the effects of treatment on bone architecture, right femora were scanned 
using a nominal voxel size of 10 microns (Skyscan 1172, Bruker). Scans were performed using a 
0.7-degree angle increment, two frames averaged, through a 0.5mm Al filter (V = 60kV, I = 
167µA). Images were reconstructed (nRecon) and calibrated to hydroxyapatite-mimicking 
phantoms (0.25 and 0.75 g/cm3 Ca-HA). For each femur, a cancellous region was selected at the 
distal metaphysis, extending 1-mm proximally from the most proximal portion of the growth plate, 
and then quantified using CT Analyzer (CTAn). To obtain cortical architectural properties, a 1-
mm cortical region was selected at approximately 50% length of the femur, then analyzed with a 
custom MATLAB script.[27] Additionally, right tibiae were scanned at the mid-diaphysis to obtain 
cortical geometry used for fracture toughness testing as indicated below.  
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2.4 Three-point Bending Mechanical Testing to Failure 
Right femora were tested to failure in three-point bending (support span at 8 mm) with the 
anterior surface in tension. The bones were loaded at a displacement control rate of 0.25 mm/sec 
while the sample remained hydrated with PBS. Cross-sectional cortical properties at the femoral 
mid-diaphysis were obtained from µCT images as described above. These properties were used to 
map load-displacement data into stress-strain data using standard engineering equations as 
previously reported.[28] 
 
2.5 Fracture Toughness Testing 
Fracture toughness of the right tibiae was measured using a linear elastic fracture 
mechanics approach, as described previously.[29, 30] Briefly, a notch was made on the anteromedial 
aspect of the tibia, at approximately 50% of the length, using a scalpel blade lubricated with a 1 
μm diamond suspension. The tibiae were notched into the medullary cavity to a depth not 
exceeding the bone’s midpoint. They were then tested to failure in 3-point bending at a 
displacement control rate of 0.001 mm/sec with the notched surface in tension. The load point was 
positioned directly above the notch site.  
After mechanical testing, the bones were cleansed of marrow and dehydrated using an 
ethanol gradient (70-100%) and a vacuum desiccator. Following sputter-coating with gold, the 
cross-sectional fracture surface was imaged with scanning electron microscopy (SEM). The angles 
of stable and unstable crack growth were obtained from the images and, along with geometric 
properties from µCT data, a custom MATLAB script calculated stress intensity factors for crack 
initiation, maximum load, and fracture instability.  
 
2.6 Statistical Analysis 
All data were checked for assumptions of normality and homogeneity of variance, and 
violations were corrected using transformations. For each genotype independently, a One-Way 
ANOVA with post-hoc Dunnett’s test was used to statistically analyze the effect of each treatment 
versus control. Analysis was performed using GraphPad Prism (v.8) with a significance level at 
α=0.05.  
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3. RESULTS 
 
3.1 Treatment contributed to gains in trabecular architecture and mineralization 
Bone volume fraction and bone mineral density in the femoral distal metaphysis were 
significantly greater compared to control in both genotypes with ZOL monotherapy and 
combination treatment, but not with RAL monotherapy (Figure 1, Supplemental Table 1 and 3). 
Similarly, in both genotypes, trabecular number was significantly greater and trabecular spacing 
significantly lower with ZOL alone and with combinatorial therapy but not with RAL alone. 
Although trabecular thickness trended upward with RAL in both WT (+7.1%) and OIM+/- 
(+5.8%), it only reached significance with combination treatment in both genotypes (WT: +24.7%; 
OIM+/-: +20.9%). Tissue mineral density (TMD) was significantly elevated with the combination 
treatment in both genotypes. Additionally, TMD significantly increased in WT mice with RAL 
monotherapy. Although the property trended upward in OIM+/- with RAL alone, it did not reach 
significance. ZOL had no effect on TMD in either genotype.  
 
 
 
 
Figure 1. Treatment effects on (A) Bone Volume Fraction (BV/TV), (B) Bone Mineral Density (BMD),  (C) Trabecular 
Number (Tb.N), (D) Trabecular Separation (Tb.Sp), (E) Trabecular Thickness (Tb.Th), and (F) Tissue Mineral Density 
(TMD) in the distal femoral metaphysis. Significant change from control indicated by ‘*’ at p<0.05.  
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3.2 Treatment had no effect on cortical geometry at the femoral mid-diaphysis 
Despite the large changes in cancellous bone architecture, cortical geometric properties 
showed no significant changes with either monotherapy or combinatorial treatment at the 
femoral mid-diaphysis (Table 1).  
 
Table 1. Cortical Geometry at the Femoral Mid-Diaphysis.  
  WT   OIM+/- 
  Control RAL ZOL RAL+ZOL p-value   Control RAL ZOL RAL+ZOL p-value 
Total CSA 
(mm2) 
2.031 ± 0.174 2.068 ± 0.193 2.011 ± 0.216 2.053 ± 0.19 0.877   1.897 ± 0.267 1.837 ± 0.167 1.965 ± 0.31 1.834 ± 0.194 0.712 
Marrow Area 
(mm2) 
1.051 ± 0.1 1.047 ± 0.116 1.027 ± 0.104 1.028 ± 0.102 0.891   0.974 ± 0.128 0.902 ± 0.096 0.979 ± 0.157 0.906 ± 0.116 0.273 
Cortical Area 
(mm2) 
0.98 ± 0.113 1.02 ± 0.084 0.984 ± 0.129 1.024 ± 0.107 0.583   0.923 ± 0.179 0.935 ± 0.092 0.987 ± 0.176 0.929 ± 0.091 0.951 
Cortical 
Thickness (mm) 
0.227 ± 0.021 0.235 ± 0.01 0.23 ± 0.021 0.238 ± 0.017 0.371   0.225 ± 0.04 0.231 ± 0.017 0.238 ± 0.036 0.229 ± 0.013 0.939 
Periosteal 
perimeter (mm) 
5.868 ± 0.231 5.921 ± 0.239 5.852 ± 0.271 5.898 ± 0.24 0.881   5.684 ± 0.357 5.63 ± 0.25 5.789 ± 0.395 5.611 ± 0.254 0.758 
Endocortical 
perimeter (mm) 
4.581 ± 0.224 4.533 ± 0.242 4.53 ± 0.282 4.5 ± 0.218 0.839   4.414 ± 0.301 4.286 ± 0.265 4.513 ± 0.543 4.247 ± 0.256 0.327 
Imax (mm4) 0.346 ± 0.064 0.366 ± 0.061 0.347 ± 0.074 0.366 ± 0.067 0.739   0.3 ± 0.084 0.301 ± 0.058 0.329 ± 0.081 0.292 ± 0.058 0.839 
Imin (mm4) 0.168 ± 0.031 0.177 ± 0.035 0.165 ± 0.041 0.174 ± 0.035 0.826   0.151 ± 0.045 0.139 ± 0.025 0.166 ± 0.073 0.142 ± 0.032 0.738 
TMD (g/cm3) 1.272 ± 0.021 1.267 ± 0.048 1.277 ± 0.024 1.28 ± 0.021 0.698   1.309 ± 0.032 1.314 ± 0.031 1.307 ± 0.035 1.314 ± 0.037 0.954 
Values are presented as mean ± standard deviation. CSA - cross sectional area; Imax - maximum moment of inertia; Imin - minimum moment of inertia; TMD 
- tissue mineral density. There was not a main ANOVA effect in any of the properties.  
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3.3 Treatments increased femoral mechanical strength and stiffness 
The majority of significant effects noted in femoral mechanical properties occurred in 
strength parameters (Figure 2, Table 2 and 3, and Supplemental Table 3). At the structural level, 
RAL monotherapy and combination treatment resulted in higher yield force in both genotypes. 
ZOL monotherapy also significantly increased the property but only in WT. Ultimate force was 
significantly elevated compared to control with combination treatment in both genotypes. In WT, 
total displacement was significantly lower with RAL and combination treatment compared to 
control. 
At the tissue level, ultimate stress was significantly higher with combination treatment 
compared to control in both genotypes. RAL alone increased ultimate stress in OIM+/- but not in 
WT. Yield stress significantly increased with all treatments in OIM+/-. Although the property 
trended up in WT, it did not reach significance (p=0.10). Higher yield stress led to greater 
resilience in OIM+/- with RAL and combination treatment versus control, but not with ZOL alone. 
Following the displacement trend, total strain in WT was significantly lower with combination 
treatment.  
A few non-strength parameters were also impacted by treatment. Stiffness was 
significantly higher with all treatments in OIM +/-, but in WT, only increased with RAL 
monotherapy and combination therapy. The combination treatment in WT also resulted in a greater 
modulus and decreased total strain compared to control.  
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Figure 2. Schematic force-displacement curves for WT (A) and OIM +/- (B). Schematic stress-strain 
curves for WT (C) and OIM +/- (D). 
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Table 3. Estimated Tissue-level Mechanical Properties From 3-Point Bending of the Femoral Mid-Diaphysis. 
  WT   OIM+/- 
  Control RAL ZOL RAL+ZOL p-value   Control RAL ZOL RAL+ZOL p-value 
Yield Stress (MPa)# 143 ± 30.8 161 ± 24.3 167.2 ± 29.5 167.3 ± 33.7 0.104   143.3 ± 24.4 187 ± 42.5** 172.5 ± 35.6* 183.2 ± 17.4** 0.002 
Ultimate Stress (MPa)*# 194.3 ± 26.7 215.5 ± 20.3 217.7 ± 35.5 236.6 ± 49.3** 0.020   179.3 ± 30.5 213.3 ± 37.1* 205.4 ± 34 224.7 ± 23.3** 0.003 
Strain to Yield (mε) 22.9 ± 3.9 21.0 ± 3.5 22.7 ± 2.8 20.1 ± 1.9 0.060   21.3 ± 4.1 21.9 ± 2.3 21.4 ± 3.8 21.3 ± 3.3 0.949 
Total Strain (mε) * 162.3 ± 63.5 113.2 ± 52 119.6 ± 57.2 104.3 ± 33.4* 0.023   72.9 ± 30.1 55 ± 20.5 60.2 ± 21.4 57 ± 16.8 0.162 
Modulus (GPa)* 6.92 ± 1.19 8.65 ± 1.6 8.33 ± 2.54 9.39 ± 2.34** 0.013   7.74 ± 2.19 9.69 ± 3.2 9.09 ± 2.11 9.76 ± 1.82 0.106 
Resilience (MPa)# 1.8 ± 0.62 1.85 ± 0.49 2.03 ± 0.35 1.83 ± 0.39 0.567   1.64 ± 0.38 2.2 ± 0.43** 2.03 ± 0.69 2.13 ± 0.4* 0.017 
Toughness (MPa) 21.3 ± 7.6 17.34 ± 6.27 18.53 ± 7.63 18.28 ± 5.71 0.456   9.66 ± 4.03 8.12 ± 2.68 9.15 ± 3.84 9.23 ± 2.78 0.650 
Values are presented as mean ± standard deviation. In the property column, a significant main One-Way ANOVA effect of treatment is indicated by '*' in 
WT and '#' in OIM+/-. A significant difference from control within each genotype is indicated by '*' for p<0.05, '**' for p<0.01, and '***' for p<0.001. 
Table 2. Structural Mechanical Properties From 3-Point Bending of the Femoral Mid-Diaphysis. 
  WT   OIM+/- 
  Control RAL ZOL RAL+ZOL p-value   Control RAL ZOL RAL+ZOL p-value 
Yield Force 
(N)*# 
12.7 ± 1.3 14.7 ± 1.6** 14.3 ± 2* 14.7 ± 1.8** 0.007   11.9 ± 2 14.1 ± 1.7** 13.7 ± 1.8 14.3 ± 2.2** 0.008 
Ultimate 
Force (N)*# 
17.6 ± 2.4 19.8 ± 2.1 18.8 ± 3.4 20.8 ± 3.1** 0.023   14.8 ± 1.6 16.2 ± 1.6 16.4 ± 2.5 17.4 ± 2.2** 0.011 
Displ. to Yield 
(µm) 
148.4 ± 30.6 138.5 ± 21.9 148.8 ± 17.3 130.6 ± 12.8 0.092   142.9 ± 18.9 147 ± 12.8 142.1 ± 20.4 142.8 ± 16.1 0.862 
Post yield 
Displ. (µm)* 
899.9 ± 417 590.8 ± 291.5 638.9 ± 395.6 539.6 ± 196* 0.029   343.8 ± 177.3 215.7 ± 120.3 261.7 ± 156.5 238.2 ± 100.6 0.096 
Total Displ.  
(µm)* 
1048.3 ± 421.5 729.3 ± 292.5* 787.8 ± 407.1 670.2 ± 197.6* 0.024   486.6 ± 181.4 362.7 ± 121.6 403.9 ± 152 381 ± 104.3 0.111 
Stiffness 
(N/mm) *# 
97.7 ± 18.9 120.1 ± 19.7** 107.9 ± 21.7 125.8 ± 14.5*** <0.001   92.4 ± 9.9 107 ± 14.5* 107.9 ± 17* 111.5 ± 16** 0.006 
Work to Yield 
(mJ) 
1.02 ± 0.23 1.11 ± 0.23 1.15 ± 0.17 1.05 ± 0.2 0.386   0.93 ± 0.25 1.13 ± 0.19 1.06 ± 0.25 1.12 ± 0.24 0.103 
Post yield 
Work (mJ) 
11.2 ± 4.29 9.46 ± 4.33 9.36 ± 4.27 9.62 ± 3.52 0.587   4.61 ± 2.49 3.1 ± 1.51 3.97 ± 2.48 3.79 ± 1.69 0.289 
Total Work 
(mJ) 
12.22 ± 4.22 10.57 ± 4.37 10.51 ± 4.37 10.67 ± 3.6 0.633   5.54 ± 2.55 4.23 ± 1.47 5.03 ± 2.5 4.9 ± 1.82 0.431 
Values are presented as mean ± standard deviation. In the property column, a significant main effect of treatment is indicated by '*' in WT and '#' in OIM+/-. A 
significant difference from control within each genotype is indicated by '*' for p<0.05, '**' for p<0.01, and '***' for p<0.001. Displ. – displacement.  
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3.4 Fracture toughness was elevated in OIM+/- with combination treatment 
Combination treatment in OIM+/- led to significantly higher stress intensity factors at 
crack initiation and maximum load at the tibial mid-diaphysis (Figure 3, Supplemental Table 2 
and 3). Neither monotherapy significantly changed fracture toughness in OIM+/-. Treatment in 
WT produced no significant effects in the stress intensity factors. 
 
 
 
  
Figure 3. Treatment effects on the stress intensity factor for crack initiation, maximum 
load, and fracture instability for OIM+/- (A) and WT (B). Significant change from control 
indicated by ‘*’ at p<0.05.  
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4. DISCUSSION 
 
Current therapeutics used to combat bone fragility are able to increase bone mass but are 
insufficient on their own to enhance bone quality and improve fracture resistance in some 
diseased states. Targeting different mechanisms with a combination treatment could be a 
powerful technique to enhance bone on both a macroscopic (mass) and microscopic tissue 
(quality) level. The goal of this study was to investigate how the mass-based effects of 
bisphosphonates, combined with the tissue-level improvements seen with raloxifene, would 
improve bone quantity, quality, and fracture resistance. The results demonstrate that ZOL and 
RAL could be used together to enhance trabecular architecture, cortical mechanical properties, 
and tissue fracture toughness more than either treatment alone, a finding that was more 
pronounced in diseased bone. 
For trabecular architecture, the combination treatment appeared to be driven by the 
dominant effects of ZOL, with greater bone volume fraction, greater trabecular number, and 
lower trabecular spacing. ZOL alone did not impact trabecular thickness or TMD. These 
trabecular findings are consistent with previous research investigating BP use in adolescent OI 
mice.[31-34]  The results are unsurprising as at this relatively young age, trabecular bone is often 
lost with longitudinal growth coupled with resorptive modeling in mice. BP use effectively 
inhibited this modeling and bone volume was maintained.  
Although RAL exhibited an overall minimal effect on trabecular structure, there was a 
trend toward increased trabecular thickness and TMD. Similar changes to thickness and TMD 
have previously been noted with RAL use.[26, 32] The properties did not change with ZOL alone, 
but with combination therapy, the improvements were synergistic in both genotypes, producing 
greater than three times the effect of either monotherapy in most cases. Increased thickness with 
RAL was likely initiated by the cellular anabolic effects of RAL as a SERM drug. When adding 
ZOL, the resorptive modeling that would have otherwise occurred at the struts was inhibited, and 
thickness was maintained and elevated compared to control. It is unclear why TMD was 
amplified with combination treatment, but this positive effect deserves additional investigation. 
Although trabecular architecture was enhanced and this positive effect cannot be 
overlooked, clinical fractures typically occur at cortical locations in the diaphysis rather than the 
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metaphyses, and improved trabecular features does not necessarily address the problem of 
fracture resistance. In this current study, there were no significant effects on cortical geometry 
with any treatment in either genotype. Previous work has shown that, in cortical bone, metabolic 
activity is lower, and it was expected that ZOL would have little effect on mass. [31-34] Likewise, 
RAL is expected to have limited geometric effect in cortical locations. However, previous work 
has demonstrated significant increases in cortical thickness that were not reproduced in this 
study. [26, 32] This discrepancy could be due to differences in animal age, as one of the studies 
investigated mice at from 16 weeks to 24 weeks, or phenotype severity, as the other study used 
homozygous OI mice bred on a mixed B6/C3H background.  
Regardless, the lack of geometric changes suggests that any differences in mechanical 
properties are most likely driven by changes at the intrinsic tissue level. Greater intracortical 
porosity has been demonstrated in pediatric OI bone, which negatively impacts cortical 
mechanical integrity[35, 36], but intracortical porosity was not observed here. Given that the 
majority of clinical fractures occur at cortical regions in OI pediatric patients, further insight on 
pharmacological improvements of cortical bone porosity and quality should be investigated. 
The significant effects of treatment versus control on mechanical behavior were mostly 
related to strength parameters. The tissues had increased stiffness with all the treatments. ZOL 
had a modest impact on its own, significantly increasing yield force in WT and yield stress in 
OIM+/-. The effects of RAL alone were more compelling and drove the changes seen with 
combination treatment. Yield stress increased in OIM+/- with RAL and combination treatment 
which led to a significant increase in resilience, indicating the bones were able to absorb more 
energy before yielding.  
Previous work with RAL has demonstrated enhanced post-yield mechanical behavior 
with bone soaked ex-vivo, one year of treatment in female beagles, and with RAL administration 
after first treating with ZOL in mice. [13, 23, 32] In this study, treatment groups did not show 
increased post-yield properties and, in some cases, surprisingly decreased. This is common with 
BP use, but a significant decrease in post-yield behavior with RAL was unexpected. Previous 
work with OI mice at this age range demonstrated no significant effect of in-vivo RAL treatment 
on any whole bone mechanical properties.[26] In the current study, control groups from both 
genotypes showed far more total deformation than expected, causing treatment effects to appear 
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significantly lower compared to control. The reason behind these effects is not clear, but it 
removed the possibility of detecting any potential post-yield effects of treatment.  
Perhaps the most important result here is that the combination treatment improved stress 
intensity factors at crack initiation and maximum load in the diseased mice. This type of test 
reflects true material-level properties in bone and indicates improved fracture resistance in 
diseased bone with this combined treatment. It was hypothesized that increasing mass at the 
same time as improving quality would benefit fracture resistance more than either monotherapy 
alone. The argument for this is that when more bone is formed in the presence of a compound 
that enhances quality, the combined tissue-level impact should be large. Because ZOL did not 
improve cortical mass as expected, and RAL alone did not improve fracture toughness, the 
improvement with combined treatment is curious. The mechanism behind this change is not 
known, but future investigation of tissue quality changes should help to clarify. Treatment did 
not impact WT mice, likely because it is difficult to improve bone that is already of good quality. 
Similar to the results of this study, fracture toughness has not been shown to improve with BP 
treatment. In skeletally mature rabbits, ZOL injections did not improve fracture toughness in 
ulnar sections.[37] In humans, long term BP use has additionally been shown to compromise 
fracture toughness on femoral corticocancellous biopsies.[38]  
BPs are the only FDA approved drug for pharmaceutical treatment of Osteogenesis 
Imperfecta. A recent review paper compiled over 15 years of clinical trials investigating BPs use 
in patients with OI. It was determined that while both oral and IV BPs substantially improved 
BMD, it was unclear whether BPs consistently improve fracture resistance and decrease fracture 
risk[39]. Continuous use of BPs in children and teenagers with OI has revealed some negative 
impacts on bone health, including microdamage accumulation and delayed healing.[40-42] These 
findings confirm the need for treatments that focus on improving bone quality, in addition to 
quantity, to improve skeletal fragility and prevent fracture. The fact that we have shown a 
positive combined treatment effect on measures of fracture resistance in diseased bone, 
effectively returning these properties to near WT control levels, is promising and future work 
will focus on treatment strategies to optimize this effect.   
There are some limitations to our study. Male mice were chosen in attempt to reduce the 
metabolic effects of RAL and utilize its cell-independent mechanism. This was intentional but 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Powell 16 
 
 
could limit the findings. The study also did not directly compare the effects of treatment on bone 
cell activity or on extracellular matrix quality. Future work should be conducted to assess 
treatment effects on both sexes along with further investigation of cellular and matrix activity in 
the diseased condition. With fracture toughness testing, sample sizes were not consistent across 
groups. Numerous bones were accidentally broken during the notching process. It was also 
difficult to determine the transition lines of crack propagation for several samples. Homozygous 
(OIM-/-) mice were originally included in this study. However, the severity of the phenotype 
caused numerous spontaneous fractures in the untreated mice, and only 2 control samples were 
usable for analysis. Lastly, the age of the mice used here could be controversial. The mice 
received treatment from 8 weeks to 16 weeks. The age group was chosen to mirror the rapid 
growth during human adolescence, and potentially when treatment might be started in humans 
with OI. This age could have led to the high deformation in the control groups due to rapid 
modeling and slow mineralization. It is also problematic because it does not coincide with an age 
that humans receive RAL, as RAL is typically only administered in older adults. Future studies 
will also investigate the effects of combined treatment in older animals, following skeletal 
maturity. 
The use of RAL has some limitations in itself. Although RAL possesses beneficial 
intrinsic effects, it may not necessarily be the most ideal drug to pursue for combinatorial 
therapy. RAL suppresses bone loss as a selective estrogen receptor modulator (SERM), but this 
estrogen therapy produces adverse effects such as hot flashes and increased thrombosis risk, 
making it a problematic treatment. The estrogen receptor binding also prevents usage in some at-
risk patient populations including children, specifically those with OI.[43, 44] Other drugs could be 
considered for a combination treatment. Recent work has shown positive outcomes in OI patients 
and OI mice treated with sclerostin antibody and denosumab.[34, 45, 46]  A more appropriate 
therapeutic for combination treatment might be parathyroid hormone (PTH) as its anabolic 
mechanism has been shown to create better quality new bone.[47] Combination of PTH and 
alendronate has previously been studied clinically for osteoporosis treatment, but results did not 
indicate any remarkable benefit compared to either monotherapy.[48-50] In OI patients, PTH has 
been shown to positively impact BMD, but comparison to BP use or a combination treatment 
was not studied.[51] These compounds, amongst others, should be investigated deeper to 
determine an ideal combination, concentration, and dosing schedule. Ideally, there is a need to 
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develop pharmaceuticals that, like RAL, directly target collagen and the extracellular matrix to 
improve quality at the microscopic level, without acting as a SERM.[14]  
In conclusion, the current study shows beneficial effects of combination therapy, 
enhancing quality of diseased bone neither treatment could accomplish alone. Utilizing the mass-
based effects of ZOL with the tissue material changes of RAL, combined therapy improved 
fracture toughness and led to increases in trabecular architecture and cortical mechanics in 
diseased animals. Combinatorial treatments should be considered for future therapies to optimize 
patient care and bone health.  
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